Navigation Links
Solos Endoscopy Finishes the 3rd Quarter Strong
Date:10/21/2011

BOSTON, Oct. 21, 2011 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) announced today that the Company finished the 3rd Quarter strong with sales revenues during the three months ended September 30, 2011 in the amount of $86,717.40.  The revenue for the third quarter is a result of instrument sales to over sixty Hospitals, Clinics, Healthcare Centers, Medical Centers and Surgery Centers across the United States.

Solos Breast Endoscopy component sales accounted for approximately 39.5% of the total sales revenue for the third quarter or $34,290. The MammoView® instrument line, designed exclusively for breast endoscopy, has become crucial to early breast cancer screening as a method to significantly reduce breast cancer death rates. The Solos MammoView® Breast Endoscopy System is designed to distinguish and inspect suspicious pre-cancerous lesions that are undetectable by other methods as well as complement existing diagnosis and treatment options with direct endoscopic observation.

"We're proud of our efforts during the 3rd Quarter, and we anticipate continued sales growth as we finish out the year," stated Bob Segersten, President of Solos Endoscopy, Inc.

The Company recently announced its intentions to donate 5% of its sales from the MammoView® Breast Endoscopy Instrument line for the month of October to support breast cancer awareness through education and early detection. The Company expects to post its full unaudited financial results for the quarter ended September 30, 2011 on the OTC Markets Group website within in the next thirty days.

About Solos Endoscopy, Inc.:Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.CONTACT:

Amanda Segerstenrsegersten@solosendoscopy.com
'/>"/>

SOURCE Solos Endoscopy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Solos Endoscopy to Support National Breast Cancer Foundation With Sales of Its MammoView® Breast Endoscopy Components to US Hospitals
2. Solos Endoscopy to Market its MammoView® Breast Endoscopy Components to US Hospitals
3. Solos Endoscopy Reports 32% Increase in Breast Endoscopy Sales
4. Solos Endoscopy to Reduce Debt by Over $620,000
5. Solos Endoscopys MammoView® System Proves Crucial to Early Breast Cancer Detection
6. Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction
7. Solos Endoscopy, Inc. To Launch New Corporate Website
8. Solos Endoscopy, Inc. Strengthens Current Line of Laparoscopic Instruments
9. Solos Endoscopy, Inc. To Introduce New Urology Instrument Line
10. Solos Endoscopy, Inc. Reports $34,291 in Sales Revenue for January 2011
11. Solos Endoscopy, Inc. Reports $90,005 in Sales Revenue for Fourth Quarter 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... , Sept. 18, 2017 ... fields of bioinformatics and immune engineering, today ... protective avian influenza A (H7N9) vaccine. ... related to seasonal influenza and presents a ... on prior exposure to be effective. Using ...
(Date:9/12/2017)... SAN FRANCISCO , Sept. 12, 2017 /PRNewswire/ ... Lifecycle Management Solutions (VLMS), is pleased to announce ... as a member of its Board of Directors ... 2017. ValGenesis VLMS enables life science companies to ... eliminate the use of paper in this process. ...
(Date:9/7/2017)... 2017  Eli Lilly and Company (NYSE: ... operations to more efficiently focus resources on developing ... Global workforce reductions, including those from a U.S. ... approximately 3,500 positions. With the ... of approximately $500 million that will begin to ...
Breaking Medicine Technology:
(Date:9/26/2017)... ... ... Founded as an independent institute in 1968, The Glenholme School devoted ... 2018, Glenholme will celebrate its first 50 years and set a course for the ... ponies, was generously donated by Jean White Van Sinderen to Devereux in 1968. The ...
(Date:9/26/2017)... ... September 26, 2017 , ... The Organizing ... and tactical plans for Pittcon 2018. As of July 1, Adrian C. Michael, ... his named vice president, Charles Gardner, (ChemImage Corporation) and selected chairs. ...
(Date:9/26/2017)... ... September 26, 2017 , ... “Childhood Memories of a ... draw readers back, and help them relive their own youth. “Childhood Memories of a ... operator in the US Navy for nine years. He received his BS from ...
(Date:9/26/2017)... (PRWEB) , ... September 26, 2017 , ... Time out ... and a little boy's newfound understanding that even grownups make mistakes. “Time Out for ... Southwestern United States for her entire life and whose passion for children inspired her ...
(Date:9/25/2017)... ... September 25, 2017 , ... The Renal Support Network (RSN) is ... improved functionality and enhanced rich content focused on RSN’s mission to empower people who ... hopeful about their future. , Our unique website is loaded with hundreds of ...
Breaking Medicine News(10 mins):